Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.29
- Piotroski Score 3.00
- Grade Buy
- Symbol (EYEN)
- Company Eyenovia, Inc.
- Price $0.52
- Changes Percentage (4.3%)
- Change $0.02
- Day Low $0.50
- Day High $0.54
- Year High $2.57
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.74
- Trailing P/E Ratio -1.03
- Forward P/E Ratio -1.03
- P/E Growth -1.03
- Net Income $-27,261,096
Income Statement
Quarterly
Annual
Latest News of EYEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
'Teen Mom' Star Cheyenne Floyd and Zach Davis Are 'Trying to Get Pregnant': 'Send Us Good Baby Vibes' (Exclusive)
Cheyenne Floyd and Zach Davis attended a kids fashion show where their daughter Ryder walked the runway. The couple, who have a son together, expressed their desire to expand their family, hinting at ...
By PEOPLE.com | 3 days ago -
From queen to empress: Ursula von der Leyen's power grab
The unveiling of 26 commissioners by Ursula von der Leyen showcased her consolidated power in the EU. By strategically reshuffling roles and removing dissenting voices, she solidified her control, ear...
By POLITICO | 1 week ago -
Von der Leyen names European Commission's new top team
EU Commission President Ursula von der Leyen appointed Spain's Teresa Ribera as antitrust commissioner, Estonia's Kaja Kallas for foreign policy, and Lithuania's Andrius Kubilius as defense commission...
By CNBC | 1 week ago
